Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2017 /
Clinical advances in treating colorectal cancer

8th - 12th Sep 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.09.17
Views: 850

Prof Michael Geißler - Klinikum Esslingen, Esslingen am Neckar, Germany

Prof Geißler speaks with ecancer at ESMO 2017 about recent trials in treating colorectal cancer presented at the congress.

He notes the Prodige 18 trial of bevacizumab and the Tricolore trial of combination therapy as stand-out presentations.

Prof Geißler also spoke about his work in the VOLFI trial of triplet therapy for CRC, here.

ecancer's filming has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence